Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio

On June 21, 2023 Quest Diagnostics (NYSE:DGX), the nation’s leading provider of diagnostic information services, reported that it has completed its previously announced acquisition of Haystack Oncology (Press release, Quest Diagnostics, JUN 21, 2023, View Source [SID1234632832]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based on circulating tumor DNA (ctDNA), to aid in the early detection of residual or recurring cancer and better inform therapy decisions. Quest expects to incorporate this MRD technology into the development of new blood-based clinical lab services for solid tumor cancers available beginning in 2024.